MT-MMPs play pivotal roles in cancer dissemination

Clinical and Experimental Metastasis

Volumn 19, Issue 3, 2002, Pages 209-215

  Yana, Ikuo ^a   Seiki, Motoharu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cancer; Extracellular matrix; MMP; MT MMP; Proteinase

Indexed keywords

CELL ADHESION MOLECULE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL CELL; CANCER CELL; ENZYME ANALYSIS; HUMAN; HUMAN CELL; METASTASIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; CELL ADHESION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; SEQUENCE HOMOLOGY, AMINO ACID; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0036109679     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015527220537     Document Type: Review

References (78)

1. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis
2. Membrane associated matrix metalloproteinases in metastasis
3. Proteases in invasion: Matalloproteinases
4. Membrane-type matrix metalloproteinases
5. Membrane type 1-matrix metalloproteinase is involved in the formation of hepatocyte growth factor/scatter factor-induced branching tubules in Madin-Darby canine kidney epithelial cells
6. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type metalloproteinases 1, 2, and 3
7. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
8. Membrane-type I matrix metalloproteinase cleaves CD44 and promotes cell migration
9. Changing views of the role of matrix metalloproteinases in metastasis
10. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnoven
11. Mechanism od cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease
12. Cellular mechanisms for human procollagenase-3(MMP-13) activation. Evidence that MMP(MMP-14) and gelatinase A(MMP-2) are able to generate active MT1-enzyme
13. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation
14. Membrane type 4 matrix metalloproteianse (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored protease
15. Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosylphosphatidyl inositol (GPI)-anchored MMP
16. Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells
17. Proteolytic processing of membrane-type 1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface
18. Regulation of membrane type-1 metalloproteinase activation by proprotein convertases
19. A matrix metalloproteinase expressed on the surface of invasive tumor cells
20. Activation of a recombinant membrane type 1 matrix metalloproteinase (MT1-MMP) bu furin and its interaction with tissue inhibitor of metalloproteinases (TIMP-2)
21. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity
22. Mechanism of cell surface activation of 72-kDa type IV collagenase-Isolation of the activated form of the membrane metalloprotease
23. Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2
24. Mutation analysis of membrane type-1 matrix metalloproteinase (mt1-mmp), the role of the cytoplasmic tail cys574, the active site glu240, and furin cleavage motifs in oligomerization, processing, and self-proteolysis of mt1-mmp expressed in breast carcinoma cells
25. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases
26. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules
27. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5
28. Membrane-type 1 MMP (MMP-14) cleaves at three sites in the aggrecan interglobular domain
29. Identification of soluble type of membrane-type matrix metalloproteinase-3 formed by alternatively spliced mRNA
30. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2
31. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors
32. Leukolysin/MMP25/MT6-MMP: A novel matrix metalloproteinase specifically expressed in the leukocyte lineage
33. Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain
34. Expression, purification and characterization of recombinant mouse MT5-MMP protein products
35. Human MT6-matrix metalloproteinase: Identification, progelatinase A activation, and expression in brain tumors
36. Biochemical characterization of the catalytic domain of membrane-type 4 matrix metalloproteinase
37. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis
38. Matrix metalloproteinases
39. The TIMP2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A. A kinetic study
40. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads
41. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion
42. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I
43. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: Associated activation of gelatinase A, gelatinase B and collagenase 3
44. Biochemical characterization of human collagenase-3
45. Activity of type IV collagenases in benign and malignant breast disease
46. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis
47. MT-MMP expression and localisation in human lung and breast cancers
48. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses
49. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas
50. Analysis of MT1-MMP and MMP2 expression in human gastric cancers
51. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas
52. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stroma cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy
53. Membrane-type matrixmetalloproteinase-1 (MT1-MMP) gene is overexpressed in highly invasive hepatocellular carcinomas
54. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas
55. Significance of membrane type 1 matrix metalloprotemase expression in breast cancer
56. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer
57. Increased expression of membrane type 1-matrix metaloproteinase in head and neck carcinoma
58. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas
59. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: Possible implications for the role of desmoplastic fibroblasts
60. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen
61. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro
62. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors
63. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas
64. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
65. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
66. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
67. Transmembrahe/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion
68. Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain
69. Three-dimensional type 1 collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells
70. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
71. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo
72. MMP inhibitors: Experimental and clinical studies
73. Matrix metalloproteinases in tumor invasion and metastasis
74. Protease inhibitors: Role and potential therapeutic use in human cancer
75. Matrix metalloproteinases: Biologic activity and clinical implications
76. Tumor progression: Defining the soil round the tumor seed
77. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
78. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma